BrightGene Bio-medical Technology(SH:688166) Shang Hai Zheng Quan Bao·2025-09-05 22:04Group 1 - The company will participate in a collective performance briefing for the innovative drug industry on September 16, 2025, from 15:00 to 17:00 [2][6][7] - Investors can submit questions from September 9 to September 15, 2025, through the Shanghai Stock Exchange Roadshow Center or via the company's email [2][8] - The briefing will be conducted in an interactive online format, allowing for real-time communication regarding the company's semi-annual performance and financial indicators [3][5] Group 2 - The company issued 4.65 million convertible bonds with a total value of 465 million yuan, which began trading on January 27, 2022 [11] - The initial conversion price for the bonds was set at 35.68 yuan per share, later adjusted to 35.56 yuan and subsequently to 35.05 yuan due to corporate actions [12][13] - The company has indicated that the redemption conditions for the bonds may be triggered if the stock price remains above 130% of the conversion price for a specified period [15][19]